IP Library Granted Patent US 8,232,309
Granted Patent B2
US 8,232,309 · App. 11/588,713 · Granted Jul 31, 2012

Prodrugs of compounds that inhibit TRPV1 receptor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,232,309
App. No.
11/588,713
Granted
Jul 31, 2012
Kind
B2
Abstract

Compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.

Claims (151)

1. A compound of formula (I)

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug or a combination thereof, wherein

A is cyclopently

R 1 is alkyl, cycloalkyl, alkenyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

wherein

R 4 is —C(O)—O—(CH 2 ) m R 5 , —C(O)(CH 2 ) n —R 6 , —(CH 2 ) r —R 7 , —C(O)R 8 , or —CH 2 (H)(OH)R 9 ;

m is 1, 2, or 3;

n is 1, 2 or 3;

r is 1, 2 or 3;

t is 0, 1, 2, 3 or 4;

u is 0, 1, 2 or 3;

R 5 is —O—P(O)(OR A )(OR A ), —P(O)(OR A )(OR A ), —OR A , —OC(O)(R A ), heterocycle, —C(O)OR A , —C(O)N(R B ) 2 , —C(O)(R A ), —NR A R B , or —N(R B )C(O)OR A ,

R 6 is —OC(O)(R A ), —OR A , —C(O)OR A , —NR A R B , —OP(O)(OR A )(OR A ), or —P(O)(OR A )(OR A );

R 7 is heterocycle, —OC(O)(R A ), —OC(O)(hydroxyalkyl), —OP(O)(OR A )(OR A ), or —P(O)(OR A )(OR A ),

R 8 is heterocycle or N(R 8a )(R 8b ) wherein R 8a and R 8b are independently hydrogen or alkyl;

R 9 is alkoxyalkyl, —C(O)OR A , -alkyl-N(R B )C(O)OR A , or heterocyclealkyl;

R A is hydrogen, alkyl, alkoxyalkyl, aryl or arylalkyl;

R B is hydrogen or alkyl;

the heterocycle and the heterocycle moiety of the heterocyclealkyl, represented by R 5 , R 7 , R 8 , and R 9 , are each independently substituted with 0, 1, 2 or 3 substituents independently selected from the group consisting of alkyl, haloalkyl, alkoxy, haloalkoxy, —C(O)OH, -alkyl-C(O)OH, and —N(Z A )(Z B );

Z A and Z B are each independently hydrogen, alkyl, —C(O)alkyl, formyl, aryl, or arylalkyl; and

the aryl and the aryl moiety of the arylalkyl, represented by R A , Z A and Z B are each independently substituted with 0, 1, 2 or 3 substituents selected from the group consisting of alkyl, haloalkyl, alkoxy and haloalkoxy.

2. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, alkenyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

R 4 is —(CH 2 ) r —R 7 .

3. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

R 4 is —C(O)(CH 2 ) n —R 6 .

4. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

R 4 is —CH 2 C(H)(OH)R 9 .

5. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

R 4 is —C(O)R 8 .

6. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, halogen or haloalkyl;

R 2 is heterocyclealkyl;

R 3 is

R 4 is —C(O)—O—(CH 2 ) m R 5 .

7. The compound of claim 6 , wherein

R 5 is —O—P(O)(OR A )(OR A ).

8. The compound of claim 6 wherein

R 5 is —P(O)(OR A )(OR A ).

9. The compound of claim 6 wherein

R 5 is —OR A .

10. The compound of claim 6 wherein

R 5 is —OC(O)(R A ).

11. The compound of claim 6 wherein

R 5 is heterocycle.

12. The compound of claim 6 wherein

R 5 is —C(O)OR A .

13. The compound of claim 6 wherein

R 5 is selected from the group consisting of —C(O)R A , —N(R B )C(O)OR A , —NR A R B , and —C(O)N(R B ) 2 .

14. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

R 4 is —C(O)R 8 .

15. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

R 4 is —CH 2 C(H)(OH)R 9 .

16. The compound of claim 1 , wherein

R 1 is alkyl, cycloalkyl, halogen or haloalkyl;

R 2 is hydrogen;

R 3 is

R 4 is selected from the group consisting of —C(O)—O—(CH 2 ) m R 5 , —C(O)(CH 2 ) n —R 6 , and —(CH 2 ) r —R 7 .

17. A compound selected from the group consisting of

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-morpholin-4-ylethyl)-1H-indazol-4-yl]urea;

2-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-oxoethyl acetate;

N-{1-[(benzyloxy)acetyl]-1H-indazol-4-yl}-N′-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]urea;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(methoxyacetyl)-1H-indazol-4-yl]urea;

4-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-4-oxobutanoic acid;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea trifluoroacetic acid salt;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-(1-glycoloyl-1H-indazol-4-yl)urea;

5-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-5-oxopentanoic acid;

2-(phosphonooxy)ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-(benzyloxy)ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-hydroxyethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-[(di-tert-butoxyphosphoryl)oxy]ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

3-(benzyloxy)propyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

3-hydroxypropyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

3-[(di-tert-butoxyphosphoryl)oxy]propyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

3-(phosphonooxy)propyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(hydroxymethyl)-1H-indazol-4-yl]urea;

{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}methyl acetate;

{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}methyl 3-hydroxypropanoate;

{[bis(benzyloxy)phosphoryl]oxy}methyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

(phosphonooxy)methyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

dibenzyl 3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-3-oxopropyl phosphate;

3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-3-oxopropyl dihydrogen phosphate;

[bis(benzyloxy)phosphoryl]methyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonic acid;

[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonic acid triethylamine salt;

2-methoxyethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

(2-oxo-1,3-dioxolan-4-yl)methyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-(benzyloxy)ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-hydroxyethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-(benzyloxy)-2-oxoethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-{[(benzyloxy)carbonyl]amino}ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]acetic acid;

2-aminoethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate hydrochloride;

2-ethoxy-2-oxoethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

(diethoxyphosphoryl)methyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-(diethylamino)-2-oxoethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-oxopropyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-(acetyloxy)ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

2-(dimethoxyphosphoryl)ethyl 4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazole-1-carboxylate;

[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonic acid, diethylaminoethanol salt;

[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonic acid, triethanolamine salt;

[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonic acid, piperazine salt;

[({4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}carbonyl)oxy]methylphosphonic acid, N-methyl-D-glucamine salt;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-hydroxy-3-methoxypropyl)-1H-indazol-4-yl]urea;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[2-(2-hydroxy-3-methoxypropyl)-2H-indazol-4-yl]urea;

methyl 3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropanoate;

methyl 3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-2H-indazol-2-yl}-2-hydroxypropanoate;

tert-butyl 3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropylcarbamate;

3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-1H-indazol-1-yl}-2-hydroxypropanoic acid;

3-{4-[({[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]amino}carbonyl)amino]-2H-indazol-2-yl}-2-hydroxypropanoic acid;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[2-(2-hydroxy-3-morpholin-4-ylpropyl)-2H-indazol-4-yl]urea;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(2-hydroxy-3-morpholin-4-ylpropyl)-1H-indazol-4-yl]urea;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-{1-[(4-methylpiperazin-1-yl)carbonyl]-1H-indazol-4-yl}urea;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-{2-[(4-methylpiperazin-1-yl)carbonyl]-2H-indazol-4-yl}urea;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea;

N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N′-[1-(N,N-dimethylglycyl)-1H-indazol-4-yl]urea, hydrochloride salt;

((R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(2-methoxyethoxy)acetyl)-1H-indazol-4-yl)urea;

1-((R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(3,5,5-trimethylhexanoyl)-1H-indazol-4-yl)urea;

2-ethylhexyl 4-(3-((R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylate;

(R)-1-(1-(2-(2-butoxyethoxy)acetyl)-1H-indazol-4-yl)-3-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea;

3-(dimethylamino)propyl 4-(3-(4-cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)ureido)-1H-indazole-1-carboxylate;

1-(4-cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)urea trifluoroacetate;

1-(5-cyclopropyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)urea hydrochloride;

1-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)-3-(4-(3,3-dimethylbutyl)-5-fluoro-2,3-dihydro-1H-inden-1-yl)urea;

(R)-1-(4-cyclopropyl-5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(dimethylamino)acetyl)-1H-indazol-4-yl)urea; and

(R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1-(2-(methylamino)acetyl)-1H-indazol-4-yl)urea hydrochloride;

18. A pharmaceutical composition comprising a therapeutically effective amount of one or more compound of formula (I) as described in claim 1 , or a therapeutically acceptable salt thereof, or combination thereof, and a pharmaceutically acceptable carrier.

19. A method of treating neuropathic pain, inflammatory pain, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.

20. A method of treating thermal hyperalgesia, bladder overactivity or urinary incontinence, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 of formula (II),

22. The compound of claim 1 of formula (III),

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030185/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2007
From: GOMTSYAN, ARTHUR R.; BAYBURT, EROL K.; KOENIG, JOHN R.; MARSH, KENNAN C.; SCHMIDT, ROBERT G., JR.; LEE, CHIH-HUNG; WANG, WEILI; DAANEN, JEROME F.; BROWN, BRIAN S.
To: ABBOTT LABORATORIES
Reel/Frame 018799/0037 →